Back to News
Market Impact: 0.25
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Source: globenewswire.com
Healthcare & Biotech
In patients without liver metastases, median progression-free survival was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet, versus 9.1 months with alpelisib plus fulvestrant. The reported efficacy results favor the gedatolisib regimens in this subgroup.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- J&J prostate cancer drug shows promising tumor responses in early trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- Fact vs. fiction: Doctors share whether peptides are safe and effective